China Rewards Breakthrough Therapy Designation to Innovent & IASO’s CAR-T Cell Therapy

On February 24, 2021 EVERSANA reported The National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted Breakthrough Therapy Designation (BTD) to Innovent and IASO Biotherapeutics’ investigational CAR-T cell therapy IBI326/CT103A for the treatment of relapsed/refractory (R/R) multiple myeloma (MM) (Press release, EVERSANA, FEB 24, 2021, View Source [SID1234575533]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IBI326/CT103A is a fully-human anti-B cell maturation antigen (BCMA) targeted CAR-T cell therapy that utilizes lentivirus as a gene vector to transfect autologous T cells, explained Innovent.

In China, BTD is reserved for new medicines that target serious conditions for which clinical evidence suggests the drug in question may demonstrate significant improvement over available therapies.

The CDE elected BTD for IBI326/CT103A based on results from an ongoing Phase 1/2 study of the CAR-T therapy being conducted in R/R MM patients in China—IBI326/CT103A is currently amid a Phase 2 pivotal trial.

Previously, clinical results demonstrating the "impressive" safety, efficacy, and durability of response of IBI326/CT103A as observed in RRMM trials were presented at the 61st Annual Meeting of the American Society for Hematology (ASH) (Free ASH Whitepaper) in 2019.

Dr. Hui Zhou, Vice President of Medical Science and Strategy Oncology at Innovent, commented, "The breakthrough therapy designation from NMPA indicated that IBI326[/CT103A] possesses great potential in treating relapsed or refractory multiple myeloma."

Jinhua Zhang, IASO BIO Founder and CEO, added, "We anticipate expedited development and review in China, allowing more patients with relapsed or refractory multiple myeloma to benefit from this therapy at the earliest possible time."